focus -WSS

focus

author：knowledge 2025-09-29 23:04:17 - browse：124

green electrocardiogram scan. -- health tech coverage from STAT — Adobe

As Bristol Myers Squibb works to build its treatment for a heart condition that can cause difficulty breathing into a blockbuster drug, it’s propped up an algorithm designed to help find more people who are affected.

The algorithm, which is part of software developed by Viz.ai, earlier this month received clearance from the Food and Drug Administration. The tool, called Viz HCM, looks at 12-lead electrocardiograms collected during routine care and flags suspected cases of hypertrophic cardiomyopathy, or HCM, for further evaluation. As part of a multi-year agreement between the companies, BMS — whose drug, Camzyos, is used to treat HCM — provided funding and scientific input for the development of the algorithm.

“BMS has a vested interest in finding more patients with HCM,” said Matthew Martinez, a cardiologist who leads Viz.ai’s HCM medical advisory board. “Why? Because they’re so philanthropic? No, they want to sell more drugs. They want to help more people by identifying more people.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Data show record exodus of life scientists from academia

knowledge

WSS

Address the ethical violations that led to 'Three Identical Strangers'

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

FDA advisers vote against ALS treatment from BrainStorm

Intercept Pharmaceuticals sells itself for less than $1 billion

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Wikipedia

focus

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Ultragenyx gene therapy for rare liver ailment succeeds in late

23andMe had bad news about my health. I wish a person had delivered it

FDA advisers vote against ALS treatment from BrainStorm

Medicare details structure of new drug price negotiation program

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

After affirmative action ruling, medical educators look to 'holistic review'

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Tori Bowie and the unacceptable rates of Black maternal death

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

leisure time

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

Address the ethical violations that led to 'Three Identical Strangers'

Let's speed up science by embracing open access publishing

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

At ASCO, AstraZeneca reports strong data for breast cancer drug

Covid vaccines: Private market messier than government rollout

knowledge

hotspot

Wikipedia

entertainment